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Methods: We reviewed patients with CDAD from January
005 to May 2008 from a 357-bed regional tertiary center,
t. Michael’s Medical Center in Newark, NJ. We analyzed the
ata to arrive at a scoring system based on age, albumin,
reatinine, and WBC. The criterias for the scoring system
ere 0 to 1 mild; 2 to 3 moderate; 4 to 5 severe; 6 to
extremely severe. One point is given for age >60; albu-
in level <2.5mg/dL is given 2 points, albumin between
.5 to 3.5mg/dL is given one point; creatinine level of
2.0mg/dL is given 2 points; creatinine between 1.0 to
.0mg/dL is given 1 point; WBC count of >20,000 cells/mL is
iven 2 points; between 10,000 to 20,000 cells/mL is given
ne point.
Results: The total number of patients with CDAD were
29 from January 2005 through May 2008. The mean age
or 2005, 2006, 2007, and 2008 were 69.1, 64.7, 68.6, and
0.1 respectively. The mean for the lowest albumin lev-
ls were 2.05, 2.04, 2.05, and 2.09mg/dL respectively.
he mean for the highest creatinine levels were 2.25,
.57, 2.58, and 2.24mg/dL. The mean for the highest WBC
ounts were 18,800, 19,400, 18,800, and 21,100 cells/mL.
he recurrence rates were 5.68%, 4.28%, 16.1%, and 8.86%,
espectively. The mortalities for 2006, 2007, and 2008 were
3.25%, 12.75%, and 18.99% respectively (pvalue <0.34). The
ean score for those who were alive were 4.50, 4.73, and
.87 respectively. The mean score for those who expired
ere 5.68, 5.45, and 5.50 respectively which showed high
orrelation with patients with mortality (p-value <0.0001).
Conclusion: There was an increase in mortality for 2008
uggesting virulent strain of C. difﬁcile. The use of the scor-
ng system will identify these patients with likelihood of high
ortality. Therefore clinicians will be able to observe these
atients with closer supervision and treat more aggressively.
oi:10.1016/j.ijid.2010.02.495
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Background: The Nocardia is described as an infectious
gent of systemic involvement especially in immunocom-
romised patients. From what we wanted to describe the
ase of a patient with type-2 diabetes mellitus developed a
evere systemic infection with fatal outcome.
Methods: We describe the case of a farmer of 62 years
rom the lower Cauca Colombia, who presented a clinical
hat begins with 2 months whitish lesions in the mouth,
ssociated with persistent fever and gradual onset of cough,
emoptysis, dyspnea, cyanosis and generalized pustule skin
c
dternational Congress on Infectious Diseases (ICID) Abstracts
esions with budding tree display and cavitary lesions in lung
nd liver abscess only, with no echocardiographic vegeta-
ions and negative blood cultures. In skin culture displayed
lamentous gram-positive bacteria compatible with Nocar-
ia.
Results: The patient has an unfavorable clinical course
ith eventual development of multiple organ failure and
eath.
Conclusion: Nocardiosis should be taken into account as
n etiologic agent in immunocompromised patients from
ural areas with systemic manifestations and progressive
linical deterioration.
oi:10.1016/j.ijid.2010.02.496
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Background: Methicillin-resistant Staphylococcus aureus
MRSA) infections of skin and soft tissues are an increas-
ng concern in hospital and community settings. Whether
ewer agents like linezolid offer efﬁcacy, safety or cost
dvantages over traditional ﬁrst line treatment with van-
omycin is not known. We conducted a systematic review
nd meta-analysis to assess the safety and efﬁcacy of line-
olid compared to vancomycin in hospitalized patients with
resumed MRSA infections of skin or soft tissue.
Methods: In October 2009, we searched MEDLINE (1950-
009), Web of Science (1900- 2009), both the Cochrane
atabase of Systematic Reviews and CENTRAL (Issue 4,
009), ClinicalTrials.gov, relevant conference proceedings
nd reference lists using no limits. We selected randomized
ontrolled trials comparing linezolid (intravenous or oral)
ersus vancomycin (intravenous) in non-surgical hospitalized
atients with MRSA-infected or suspected skin or soft tissue
nfections who were followed for a minimum of 7 days. Two
ndependent reviewers extracted data from each qualify-
ng report using a standard data collection form. We used
ochrane Collaboration’s risk of bias tool to assess method-
logical quality and data was summarized in RevMan using
andom effects models.
Results: Of 455 reports identiﬁed, 7 studies qualiﬁed
or inclusion. Linezolid was favored over vancomycin for
linical cure rate (RR 0.79; 95% CI 0.67, 0.94; P = 0.007)
nd microbiological eradication rate (RR 0.80; 95% CI 0.62,
.04; P = 0.10). Analysis of adverse events revealed no dif-
erence between the two agents (RR 0.98; 95% CI 0.76, 1.27;
= 0.90). Results for length of stay were inconclusive.
Conclusion: Our results suggest that linezolid is more
ffective than vancomycin for achieving clinical cure in
ospitalized patients with MRSA skin and soft tissue infec-
ions while adverse events are no different. However, other
mportant beneﬁts and tradeoffs such as length of stay,
esistance, and cost would be important to explore before
hanging current practice.
oi:10.1016/j.ijid.2010.02.497
